Oncocyte Announces Agreement with MultiPlan Network, Expanding Patient Access to DetermaRx™
Oncocyte Corporation has signed a significant agreement with MultiPlan, allowing access to its DetermaRx™ test for lung cancer patients across MultiPlan’s networks, covering over 60 million lives. This partnership enhances the availability of DetermaRx™, which identifies early-stage non-squamous NSCLC patients eligible for adjuvant chemotherapy, potentially improving survival rates. The collaboration is expected to increase treatment access, aligning pricing with CMS standards, thus broadening market reach.
- Access to DetermaRx™ expanded to over 60 million covered lives through MultiPlan's networks.
- Agreement aligns pricing with CMS standards, enhancing market competitiveness.
- Potential increase in survival rates for lung cancer patients identified at high risk of recurrence.
- None.
Agreement adds access for 60 million covered lives at a negotiated price in line with CMS pricing for the test
IRVINE, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, has signed an agreement with MultiPlan to participate in its networks. Through this agreement DetermaRx™ will now be available to those consumers with access to the PHCS and MultiPlan Network, MultiPlan’s national primary and complementary networks, at a pre-negotiated price per test. With more than one million healthcare providers participating in these networks and 60 million health plan members having access to MultiPlan’s services, this agreement significantly broadens the accessibility of Oncocyte’s proprietary treatment stratification test that identifies lung cancer patients with early stage non-squamous NSCLC who may benefit from adjuvant chemotherapy.
“Our agreement with MultiPlan underscores the recognition by the healthcare community of the important role DetermaRx plays in identifying lung cancer patients who are at high risk of recurrence, and whose survival rates can greatly benefit from receiving timely treatment,” said Padma Sundar, Chief Commercial Officer of Oncocyte. “MultiPlan’s partnership with hundreds of healthcare payors, along with its vast group of providers and plan members, will enable significantly expanded access to DetermaRx.”
About MultiPlan
MultiPlan is committed to helping healthcare payors manage the cost of care, improve their competitiveness and inspire positive change. Leveraging sophisticated technology, data analytics and a team rich with industry experience, MultiPlan interprets clients' needs and customizes innovative solutions that combine its payment integrity, network-based and analytics-based services. MultiPlan is a trusted partner to over 700 healthcare payors in the commercial health, dental, government and property and casualty markets. For more information, visit multiplan.us.
About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company’s tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte recently launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO™, the company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company previously announced its planned acquisition of Chronix Biomedical Inc. and its TheraSure™ CNI Monitor test, and also plans to continue with the development of DetermaMx™ as the Company seeks to expand into the blood-based monitoring market. Oncocyte’s pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.
DetermaRx, DetermaIO, DetermaMx, and DetermaTx are trademarks of Oncocyte Corporation. Therasure is a trademark of Chronix Biomedical Inc.
Oncocyte Forward Looking Statements. Oncocyte cautions you that this press release contains forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to the acquisition of Razor Genomics along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on our or any distributor’s financial and operational results, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to our or any distributor’s supply chain, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, greater than estimated allocations of resources to develop and commercialize technologies, or failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com
FAQ
What is the significance of Oncocyte's agreement with MultiPlan for OCX investors?
How many lives are covered under the MultiPlan agreement for DetermaRx™?
What benefits does DetermaRx™ offer to lung cancer patients?
When was the agreement between Oncocyte and MultiPlan announced?
How does the pricing of DetermaRx™ compare to CMS standards?
